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The accumulation of oxidized ApoB-100-containing lipoproteins in the vascular intima 
and its subsequent recognition by macrophages results in foam cell formation and 
inflammation, key events during atherosclerosis development. Agents targeting this 
process are considered potentially atheroprotective. Since natural biflavonoids exert 
antioxidant and anti-inflammatory effects, we evaluated the atheroprotective effect of 
biflavonoids obtained from the tropical fruit tree Garcinia madruno. To this end, the 
pure biflavonoid aglycones morelloflavone (Mo) and volkensiflavone (Vo), as well as the 
morelloflavone’s glycoside fukugiside (Fu) were tested in vitro in primary macrophages, 
whereas a biflavonoid fraction with defined composition (85% Mo, 10% Vo, and 5% 
Amentoflavone) was tested in vitro and in vivo. All biflavonoid preparations were potent 
reactive oxygen species (ROS) scavengers in the oxygen radical absorbance capacity 
assay, and most importantly, protected low-density lipoprotein particle from both lipid 
and protein oxidation. In biflavonoid-treated macrophages, the surface expression of 
the oxidized LDL (oxLDL) receptor CD36 was significantly lower than in vehicle-treated 
macrophages. Uptake of fluorescently labeled oxLDL and cholesterol accumulation 
were also attenuated in biflavonoid-treated macrophages and followed a pattern that 
paralleled that of CD36 surface expression. Fu and Vo inhibited oxLDL-induced ROS 
production and interleukin (IL)-6 secretion, respectively, whereas all aglycones, but not 
the glucoside Fu, inhibited the secretion of one or more of the cytokines IL-1β, IL-12p70, 
and monocyte chemotactic protein-1 (MCP-1) in lipopolysaccharide (LPS)-stimulated 
macrophages. Interestingly, in macrophages primed with low-dose LPS and stimulated 
with cholesterol crystals, IL-1β secretion was significantly and comparably inhibited by all 
biflavonoid preparations. Intraperitoneal administration of the defined biflavonoid fraction 
into ApoE−/− mice was atheroprotective, as evidenced by the reduction of the atheroma-
tous lesion size and the density of T cells and macrophages infiltrating the aortic root; 
moreover, this treatment also lowered the circulating levels of cholesterol and the lipid 
peroxidation product malondialdehyde. These results reveal the potent atheroprotective 
effects exerted by biflavonoids on key events of the oxLDL–macrophage interphase: 
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(i) atheroligand formation, (ii) atheroreceptor expression, (iii) foam cell transformation, and 
(iv) prooxidant/proinflammatory macrophage response. Furthermore, our results also 
evidence the antioxidant, anti-inflammatory, hypolipemiant, and atheroprotective effects 
of Garcinia madruno’s biflavonoids in vivo.
Keywords: atherosclerosis, oxidized lDl, macrophage, foam cell, biflavonoid, morelloflavone, volkensiflavone, 
Garcinia madruno
Abbreviations: ABC, ATP-binding cassette; ALT, alanine transaminase; Am, 
amenoflavone; AP-1, activating protein-1; ApoB-100, apolipoprotein B-100; 
ApoE−/−, apolipoprotein E-deficient; ASC, apoptosis-associated speck-like protein 
containing a CARD; AST, aspartate transaminase; ARE, antioxidant responsive ele-
ment; BCR, B-cell receptor; BF, biflavonoid fraction; CC, column chromatography; 
COX-2, cyclooxygenase 2; Cu2+, copper (II) ion; CVD, cardiovascular disease; DCF, 
dichlorofluorescein; DiI, 1,1-dioctadecyl-3,3,3,3-tetramethylindocarbocyanine 
perchlorate; DCFH-DA, 2,7-diclorofluorescein diacetate; DMSO, dimethyl 
sulfoxide; EC, endothelial cells; EDTA, ethylenediaminetetraacetic acid; ELISA, 
enzyme-linked munosorbent assay; ERK, extracellular signal-regulated kinases; 
FAK, focal adhesión kinase; Fu, fukugiside; GC, gas chromatography; GM-CSF, 
granulocyte-macrophage colony-stimulating factor; H/E, hematoxylin/eosin; 
HFD, high-fat diet; HPLC, high-performance liquid chromatography; IHC, 
immunohistochemistry; IL, interleukin; iNOS, inducible nitric oxide synthase; 
LDH, lactate dehydrogenase; LDL, low-density lipoprotein; LPS, lipopolysac-
charide; MCP-1, monocyte chemotactic protein-1; MDA, malondialdehyde; 
MFI, mean of fluorescent intensity; MIP-1, macrophage inflammatory protein 1; 
Mo, morelloflavona; MS, mass spectrometry; NF-κB, nuclear factor-κB; NLRP3, 
nucleotide-binding domain and leucine-rich repeat containing protein 3; NRF-2, 
nuclear factor erythroid 2-related factor 2; OR, oil red; ORAC, oxygen radical 
absorbance capacity; oxLDL, oxidized LDL; PBS, phosphate-buffered saline; PGE2, 
prostaglandin E2; Rac1, ras-related C3 botulinum toxin substrate 1; REM, relative 
electrophoretic mobility; ROS, reactive oxygen species; SMCs, smooth muscle 
cells; SR, scavenger receptor; TBARS, thiobarbituric acid reactive substances; 
TCR, T-cell receptor; TE, trolox equivalents; TLR, Toll-like receptor; TNF, tumor 
necrosis factor; Vo, volkensiflavone.
inTrODUcTiOn
Atherosclerotic cardiovascular diseases (CVD) are the cur-
rent major human killers worldwide. Indexes of incidence, 
prevalence, mortality, and economic impact of CVD (1) make 
them priority target diseases for public health systems and the 
scientific community. Key events in the atherosclerotic patho-
physiology are (1) dyslipidemia-associated lipoprotein retention 
in the subintimal space of particular anatomical regions of the 
arterial tree, (2) physicochemical modifications of lipoproteins 
leading to endothelial dysfunction and activation, recruitment 
of leukocytes, and the subsequent triggering of inflammatory 
cascades governed by innate and adaptive immune systems, and 
(3) uncontrolled vicious circle of inflammation and lipoprotein 
accumulation/oxidation leading to lesion growth, inestabilization, 
and eventually to clinical events (2). Both non-hematopoietic and 
hematopoietic vascular cells participate in atherogenesis. On the 
one hand, estructural cells of the arterial wall, such as endothelial 
cells (ECs) and smooth muscle cells (SMCs), play important roles 
in various events of the atherogenic response, such as mecha-
notransduction and vessel remodeling, respectively (3). On the 
other hand, the macrophage, a bone marrow-derived cell, appears 
to play a central role in all stages of the atherosclerotic process. 
For instance, the recognition of modified low-density lipoprotein 
(LDL) by macrophages via innate receptors, such as CD36, and 
the subsequent triggering of signaling pathways leading to foam 
cell formation, inflammation, proliferation, or cell death are 
considered essential proatherogenic events (3). Recent research 
emphasizes the importance of this oxidized LDL (oxLDL)-
macrophage interphase for atherosclerosis (4) and validates the 
associated events as promising therapeutic targets (5–8).
Flavonoids are a widely distributed class of phytochemicals 
present in many vegetables and fruits, with undisputed health-
promoting properties. Although clinical, epidemiological, and 
experimental data have revealed the potential of this compounds 
for prevention or treatment of many diseases, including CVD 
(9–11), the underlying putative mechanisms are multiple, com-
plex, and controversial (11, 12). In spite of this, there is an evident 
expectation that a better understanding of the mode of action 
of these intriguing molecules will guide their future intelligent 
exploitation from a dietary and/or pharmacological perspective 
(13). Biflavonoids are a class of flavonoids, which consist of 
flavonoid dimers formed by the covalent bond (C-C or C-O-C) 
between two monoflavonoids. Biflavonoids are also secondary 
metabolites but with a more restricted presence in plants, serv-
ing as chemotaxonomic markers for several species (14, 15). An 
array of biological activities, largely overlapping with those of 
flavonoids, has been reported for biflavonoids and biflavonoid-
enriched preparations from plants (15–17). Among them, anti-
oxidant, antiproliferative, or anti-inflammatory activities appear 
prominent, suggesting their potential for pharmacological 
application in the prevention or treatment of atherosclerosis and 
associated vascular diseases. However, surprisingly, very little has 
been investigated regarding the atheroprotective effects of bifla-
vonoids. A remarkable exception is the study by Pinkaew and 
collaborators, in which atherosclerosis-prone Ldlr−/− Apobec1−/− 
mice were fed morelloflavone (Mo, a prototypic biflavonoid)-
supplemented diet and a significant reduction in the size of 
atherosclerotic lesions was observed (18). Two studies reported 
that Mo altered vascular SMC and EC migration in  vitro and 
inhibited neointimal formation and tumor angiogenesis in vivo 
(19, 20), suggesting that some atheroprotective effects of this 
biflavonoid could be explained by actions on non-hematopoietic 
vascular cells. Although some studies have evidenced the effects 
of biflavonoids on the inflammatory response of mouse and 
human macrophages (16), to our knowledge, there are no reports 
on the effects of Mo or other biflavonoid in the context of the 
oxLDL–macrophage interaction.
Genus Garcinia has been reported to be the main source of 
biflavonoids and these compounds are recognized as chemotaxo-
nomic markers of Garcinia species (14). A previous phytochemi-
cal study with endemic species from northern South America 
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revealed the abundance of rotameric biflavonoids in the aerial 
parts of the tropical fruit tree Garcinia madruno (21). Several 
biflavonoids, such as Mo, volkensiflavone (Vo), or Amentoflavone 
(Am), as well as some biflavonoid glycosides such as Fukugiside 
(Fu) were identified (21, 22). Considering the paucity of informa-
tion regarding the atheroprotective effects and mechanisms of 
Mo in particular and of biflavonoids in general, as well as the 
importance of macrophages in atherogenesis, we investigated 
the effects of the most abundant biflavonoids isolated from G. 
madruno on the proatherogenic response of primary mouse mac-
rophages. We found that Mo, Vo, and/or Fu were active in vitro at 
preventing LDL oxidation, modulating CD36 scavenger receptor 
(SR) expression, attenuating foam cell formation, and inhibit-
ing inflammatory response in proatherogenic macrophages. 
Furthermore, in in  vivo experiments using ApoE-deficient 
(ApoE−/−) mice, we found that intraperitoneal (i.p.) treatment 
with a defined biflavonoid fraction (BF) from G. madruno attenu-
ated atherosclerosis development and this effect was associated 
with hypolipidemic and antioxidant activities as well as with 
reduced inflammatory macrophage and T  cell infiltrate in the 
aortic root. Our results confirm the metabolic, antioxidant, and 
immunomodulatory effects of biflavonoids in  vitro and in  vivo 
and contribute to the understanding of their pharmacological 
activities.
MaTerials anD MeThODs
animals, Diet, and reagents
Wild type and ApoE−/− (B6.129P2-Apoetm1Unc/J) C57BL/6 mice 
were obtained from Charles River (USA) and Jackson laborato-
ries (USA), respectively. Mice were bred and maintained under 
specific pathogen-free (SPF) conditions at the SPF facility of 
the Sede de Investigacion Universitaria (SIU), Universidad de 
Antioquia. This study was carried out according to the guidelines 
for the care and use of laboratory animals; all of the procedures 
were approved by the institutional animal care committee (Comite 
institucional para el cuidado y uso de los animales, Universidad 
de Antioquia). Animals were fed a standard mouse diet (LabDiet, 
USA) or a high-fat diet (HFD, adjusted calories diet 42%, Harlan 
Teklad, USA). Lipopolysaccharide (LPS) (from E. coli 0727:B8), 
2,7-diclorofluorescein diacetate (DCFH-DA), Fluorescein, 
2,2′-Azobis (2-methylpropionamidine) dihydrochloride (AAPH), 
(±)-6-Hydroxy-2,5,7,8-tetramethylchromane-2-carboxylic acid 
(Trolox), 2-thiobarbituric acid (TBA), and 1,1,3,3-tetrameth-
oxypropane were obtained from Sigma-Chemical Co. (USA). 
Cholesterol crystals were prepared following our previously 
published protocol (23). Human LDL was prepared and oxidized 
following published protocols (23, 24). For some experiments, 
oxLDL preparations (1 mg/mL) were fluorescently labeled with 
1,1-dioctadecyl-3,3,3,3-tetramethylindocarbocyanine  perchlorate 
(DiI; Invitrogen, USA) during 12 h and dialyzed against phosphate-
buffered saline (PBS) for 12 h, as described previously (23). The 
aglycone Biflavonoids Mo and Vo, as well as the morelloflavone’s 
glucoside Fu (Figure 1) were prepared from the aerial parts of G. 
madruno and purified using batch chromatography as previously 
reported (21, 22). A portion of the ethyl acetate extract (50 g) from 
G. madruno was fractionated by size exclusion chromatography 
on Sephadex LH-20 and vacuum liquid column chromatography 
(CC). In this way, a considerable purification of a biflavonoid-rich 
fraction was achieved (2.2 g). The methanolic extract was subjected 
to silica gel CC to yield Fu. Extensive CC of BF produced Mo and 
Vo. The compounds were identified on the basis of 1D, 2D nuclear 
magnetic resonance (HMQC and HMBC) spectroscopic methods 
and chemical evidence (21, 25). For in vivo experiments, a BF of 
a known composition (Mo, Vo, and Am; with an approximate 
proportion of 85, 10, and 5% by weight, respectively; purity 94%, 
as determined by high-performance liquid chromatography) was 
also prepared according to the previously described method (21, 
22). Stock solutions of pure Biflavonoids and the BF were prepared 
in dimethyl sulfoxide (DMSO) (1 mg/mL) and stored at −20°C 
for further use.
Oxygen radical absorbance capacity 
(Orac) and lDl Oxidation inhibition 
assays
For the ORAC assay, AAPH was used as a peroxyl radical 
generator, Trolox as antioxidant standard, and fluorescein as the 
fluorescent probe (26). Fluorescein, AAPH, and the samples were 
prepared in a 75 mM phosphate buffer (pH 7.4). Pure biflavo-
noids, BF or Trolox standards (25 µL) were mixed with 150 µL 
of 1 µM fluorescein and preincubated at 37°C for 30 min before 
addition of 25 µL of AAPH solution (200 mM). The fluorescence 
(485 nm excitation/520 nm emission) was measured every 2 min 
for 120 min in a Spectra Max Gemini EM fluorimeter-Molecular 
devices (New Orleans, LA, USA). The relative ORAC values 
were calculated using the differences of areas under the decay 
curves and were expressed as µmol Trolox equivalents (TE) per 
μmol biflavonoid (μmol TE μmol−1 biflavonoid) or per gram BF 
(μmol TE g−1 BF). Based on previous work, a concentration of 
10 μM was chosen to test pure biflavonoids (Mo, Vo, and Fu) in 
the ORAC assay. The BF was tested at 5.5 µg/mL (which equals 
10 µM Mo, the dominant biflavonoid in the BF). The flavonoid 
quercetin (Qu; 10 µM) was used as a positive control of known 
antioxidant activity in some ORAC assays. For interpretation, 
the higher ORAC value of a compound/preparation, the higher 
antioxidant activity. To assess the ability of Biflavonoids to protect 
LDL from oxidation, methods that measure lipid peroxidation 
(thiobarbituric acid reactive substances, TBARS assay), and the 
ApoB-100 protein electronegativity (relative electrophoretic 
mobility, REM assay) in the LDL particle were used. For TBARS, 
LDL was incubated in potassium phosphate buffer (0.1  M) to 
a final protein concentration of 5  g/L and preincubated dur-
ing 15  min with biflavonoid samples (10  µM biflavonoids or 
5.5 µg/mL BF); finally, peroxidation reaction was initiated with 
CuSO4 (40  µM), incubated for 9  h at 37°C and stopped with 
1% ethylenediaminetetraacetic acid. A TCA–TBA–HCl stock 
solution (15% w/v trichloroacetic acid; 0.67% w/v thiobarbituric 
acid; 0.1  N HCl) was added to the reaction mixture that was 
then heated at 95°C for 20 min and soon after centrifugated at 
3,000 ×  g for 15  min and, finally, absorbances of supernatants 
were read at 532 nm. For malondialdehyde (MDA) calibration 
curve, different concentrations of 1,1,3,3-tetraethoxypropane 
were prepared as external standards. The oxidation of LDL was 
FigUre 1 | Chemical structures of biflavonoids used in the study.
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expressed as nanomole of MDA per mg LDL. For REM assays, 
LDL was preincubated as above using different concentrations 
of biflavonoids or BF and after 9 h of CuSO4-induced oxidation 
samples were taken to run in agarose gel electrophoresis (120 V, 
500 mA) using barbital buffer (pH 8.7). Proteins were developed 
with Sudan black B staining (0.1% w/v in ethanol 95%).
Macrophage generation and Treatments
The in vitro effect of biflavonoids on macrophage proatherogenic 
responses [CD36 surface expression, foam cell formation, cho-
lesterol accumulation, reactive oxygen species (ROS) produc-
tion, and proinflammatory cytokine secretion] was assessed in 
primary bone marrow-derived macrophages, as previously 
reported (23). For this purpose, bone marrow cells were obtained 
from 8-week-old male C57BL/6 mice, cultured with granulocyte-
macrophage colony-stimulating factor during 9  days and the 
resulting firmly adherent cells were removed with scrapers to be 
used as a source of macrophages for all the experiments. The cul-
ture medium was RPMI 1640 (Glutamax, Gibco, USA) containing 
10% FBS, 100 U/mL penicillin, 100 µg/mL streptomycin and 0.05 
β-mercaptoetanol and cells were incubated at 37°C with 5% CO2. 
In all cases, macrophages (5 × 105 cells/mL) were pretreated with 
pure biflavonoids or the BF for 12 h and, subsequently, incubated 
with different stimuli (oxLDL, LPS, or cholesterol crystals). 
As negative controls, macrophages were treated with an equiva-
lent volume of vehicle (DMSO 0.05% in PBS). None of the mac-
rophage proatherogenic responses evaluated here were affected 
by incubations with vehicle in either basal or stimulated condi-
tions (not shown). Likewise, biflavonoids alone did not induce 
any detectable effect on resting macrophages. All reagents used 
for macrophage differentiation and treatments were endotoxin 
free, as certified by the suppliers. Regular testing for endotoxin 
contamination was performed in macrophage cultures by using a 
colorimetric LAL assay (QCL-1.000, Lonza, USA) with negative 
results (less than 0.2  EU/mL). In vitro toxicity to the different 
treatments was assessed by a cell membrane integrity viability 
test (lactate dehydrogenase assay kit, LDH; Promega, USA).
cD36 expression, Foam cell Formation, 
and cholesterol accumulation
Macrophage cultures preincubated with biflavonoids for 12  h 
(45  µM for Mo, Vo, and Fu, 25  µg/mL for BF) were further 
stimulated with oxLDL (30  µg/mL) during 36  h, washed and 
harvested with a cell scraper and cold PBS. Cell suspensions were 
then analyzed by flow cytometry to determine the surface density 
of the oxLDL receptor CD36. For the evaluation of foam cell 
formation, a cytometry-based fluorescent oxLDL uptake assay 
was used (23). Shortly, DiI-labeled oxLDL (50 µg/mL) was added 
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to biflavonoid-pretreated macrophages and further incubated for 
additional 6 h. Cells were then removed, washed, and analyzed by 
flow cytometry. In parallel uptake assays, biflavonoids-pretreated 
cells were exposed to oxLDL (30 µg/mL) for additional 36 h, and 
the intracellular accumulation of cholesterol was determined by 
gas chromatography/mass spectrometry (GC/MS), using a stand-
ardized method (23) that quantifies total cellular cholesterol. Data 
are reported as total cholesterol per 106 macrophages.
rOs Production and cytokine secretion
Biflavonoid-pretreated macrophages (90 µM for Mo, Vo, and Fu, 
50 µg/mL for BF) were washed twice with PBS and exposed to 
oxLDL (50  µg/mL) for 1  h. Cells were subsequently incubated 
with 10 µM fluorescent ROS-sensitive substrate DCFH-DA for 
30  min, washed twice, resuspended with PBS, and finally ana-
lyzed by flow cytometry to assess intracellular ROS production. 
For cytokine secretion measurements, biflavonoid-pretreated 
macrophages (45  µM for Mo, Vo, and Fu, 25  µg/mL for BF) 
were stimulated with oxLDL (25 µg/mL) or LPS (10 µg/mL) for 
12 additional hours. In another set of experiments, biflavonoid-
pretreated macrophages were primed with LPS (10 ng/mL) for 
2 h and exposed to cholesterol crystals (500 µg/mL) for additional 
10 h, to complete a total time of treatment of 24 h. Macrophage 
culture supernatants were collected and used to quantify the 
levels of interleukin (IL)-1β, IL-6, IL-12p70, TNFα, MCP-1, and 
macrophage inflammatory protein (MIP)-1α by a multianalyte 
Luminex xMAP technology assay (Milliplex xMAP, Millipore, 
USA). The limit of detection was 3.2 pg/mL for all analytes.
Flow cytometry
For CD36 surface expression, cells were first incubated with a 
purified anti-mouse CD36 antibody (clone CRF D-2712, BD 
Biosciences, USA) or an isotype control (clone M18-254, BD 
Biosciences, USA) before incubation with a FITC-rat anti-mouse 
secondary antibody (clone C10-3, BD Biosciences, USA). For 
oxLDL uptake and ROS production, cells were resuspended in 
PBS and analyzed. A Beckman-Coulter EPICS XL flow cytometer 
was used for all acquisitions (at least 10,000 events), and data 
storage and analysis was performed with WinMDI software. The 
results were reported as the percentage of CD36+, DiI+, or DCF+ 
cells and the mean of fluorescence intensity (MFI).
assessment of the atheroprotective effect 
of Biflavonoids In Vivo
Six- to eight-week-old male ApoE−/− mice (n = 12) were treated 
with i.p. injections of BF (70  mg/kg) every other day. After 
2  weeks, mice were shifted to a HFD and maintained on BF 
treatments for additional 12 weeks. Given that the low oral bio-
availability of biflavonoids (16) could lead to none/little systemic 
circulation of active compounds, i.p. administration was chosen 
for this study. A group of control mice were treated with a similar 
volume of vehicle (DMSO 0.1% in PBS). After 14  weeks, mice 
were sacrificed and the hearts/aortas were removed after in situ 
perfusion using PBS, and then fixed using 4% paraformaldehyde 
in PBS pH 7.4 for 48 h, immersed in 30% sucrose during 24 h 
and finally embedded with Shandon Cryomatrix™ (Thermo 
scientific, USA) to be stored at −20°C until use. Frozen hearts 
were processed with a cryostat (Leica Microsystems, Germany) 
to obtain 6–7-µm-thick sections of the aortic sinus as previously 
described (27). The sections were mounted on charged glass 
slides (Thermo Fisher Scientific, USA) and stained with conven-
tional hematoxylin/eosin (H/E, Sigma-Aldrich, USA) or pro-
cessed for immunohistochemistry (IHC). For IHC, aortic sinus 
sections were acetone-fixed, blocked for endogenous peroxidase 
activity, permeabilized, and incubated with a macrophage- or a 
T  cell-specific mAb (anti-mouse monocyte/macrophage, clone 
MOMA-2, or anti-CD3 antibody, clone KT3, respectively; Serotec, 
UK). A secondary horseradish peroxidase-conjugated goat 
anti-rat IgG antibody and the chromogenic substrate 3,3-diam-
inobenzidine (Serotec, UK) were used to develop antibody bind-
ing. Finally, the sections were counterstained with hematoxylin. 
Microphotographs (40× magnification) were taken, and the 
area of the atherosclerotic lesion (H/E), macrophage infiltration 
(MOMA-2+), and T  cell infiltration (CD3+) were calculated 
(in µm2) using the NIS Elements BR image analysis software 
(Nikon, Japan). Results were reported as the mean area of 9–12 
sections per animal. Lipid deposition in aortas was determined 
by Oil Red O staining (OR, Sigma). Briefly, aortas were excised 
and fixed in 10%-buffered formalin. After adventitial tissue was 
carefully removed, aortas were opened longitudinally, stained 
with OR and pinned on a green wax surface. En face images 
were obtained under stereomicroscope (SMZ; Nikon, Japan) and 
analyzed by using Image J software. The luminal OR+ surface area 
was determined and expressed as pixels2 ×  103. Blood samples 
were also collected and serum levels of total cholesterol, hepatic 
enzymes aspartate transaminase (AST) and alanine transaminase 
(ALT), as well as amylase were determined using dry chemistry 
methods (Johnson and Johnson, USA) at the Universidad de 
Antioquia Veterinary School. Circulating levels of the lipid per-
oxidation product MDA were also determined in serum samples 
by the TBARS method and expressed in micromolars.
statistical analysis
For in  vitro assays, experiments were performed in triplicate 
and the mean ± SD was reported. One-way analyses of variance 
and Newman–Keuls post hoc tests were used for multiple group 
comparisons. For in vivo experiments, results were expressed as 
the mean ±  SEM. Treated and control groups were compared 
using the unpaired Mann–Whitney or Student’s t-test. Results 
were analyzed using GraphPad Prism 5 software (GraphPad, 
USA). Statistically significant differences are indicated as follows: 
*p < 0.05, **p < 0.01, ***p < 0.001.
resUlTs
Biflavonoids attenuate the Formation of 
the atherogenic ligand oxlDl
Low-density lipoprotein particle retention and subsequent oxida-
tion in the subendothelial space is a crucial step in atherosclerosis 
initiation and progression. Therefore, prevention/attenuation 
of this step appears a logic mean to promote atheroprotection. 
We, therefore, began by investigating the antioxidant activity 
FigUre 2 | Biflavonoids inhibit low-density lipoprotein (LDL) oxidation. Oxygen radical absorbance capacity (ORAC) values of the biflavonoids Mo, Vo, and Fu 
(10 µM) were determined and expressed as micromole equivalents of Trolox per mol of biflavonoid to be compared with that of the monoflavonoid quercetin (Qu; 
10 µM) (a). ORAC value was also determined for the BF (5.5 µg/mL) and expressed as micromole equivalents of Trolox per gram to be compared with pure 
biflavonoids (B). The effect of biflavonoids (10 µM for Mo, Vo, and Fu and 5.5 µg/mL for BF) on the Cu2+-induced formation of the lipid peroxidation product 
malondialdehyde in the LDL particle was assessed by TBARS assay (c). Given the protective activity of biflavonoid preparations on LDL lipid peroxidation, a titration 
experiment of biflavonoids at the indicated concentrations (μM for Mo, Vo, and Fu; μg/mL for BF) on the electronegativity of the apolipoprotein fraction in the LDL 
was also determined by the REM assay in agarose gels (D). Also, a comparison of the protective effect of low concentration (1.5 µM for Mo, Vo, and Fu, and 
0.83 µg/mL for BF) biflavonoids on REM was performed with samples run in the same agarose gel (e). Note that the biflavonoid Mo alone does not have prooxidant 
effect [last line in (D)] under the experimental conditions used. Results are representative of at least three independent experiments.
6
Tabares-Guevara et al. Biflavonoids Are Atheroprotective In Vitro and In Vivo
Frontiers in Immunology | www.frontiersin.org August 2017 | Volume 8 | Article 923
of biflavonoids in cell-free systems. First, we tested individual 
biflavonoids for their potential to inhibit peroxy-radical-induced 
oxidation by using the conventional ORAC method. As expected, 
all biflavonoids tested were potent antioxidants (Figure 2A). Mo 
and its glucoside Fu exhibited the highest TE (above quercetin, 
used as a reference polyphenol antioxidant). When ORAC results 
were transformed into μmol TE per gram, the highest antioxidant 
capacity was observed for the BF (Figure 2B), suggesting syner-
gistic interactions among biflavonoids. We next investigated the 
antioxidant activity of biflavonoids in the more physiologically 
relevant system of Cu2+-induced LDL oxidation. When LDL 
oxidation was performed in the presence of any of the three pure 
biflavonoids, the formation of the lipid oxidation product MDA 
was reduced by approximately 50% (Figure 2C). The BF, although 
FigUre 3 | Biflavonoids inhibit surface CD36 expression on primary macrophages. Macrophages were preincubated 12 h with biflavonoids (45 µM for Mo, Vo, and 
Fu, and 25 µg/mL for BF) and, subsequently, incubated with oxLDL (30 µg/mL) for additional 36 h. The surface expression of CD36 was determined by flow 
cytometry and graphed as the percentage of CD36+ cells (a), the MFI in CD36+ cells (B) or the percentage of CD36high cells (c) based on a gating strategy shown in 
the Figure S2A in Supplementary Material. The effect of biflavonoid preparations on the expression of CD36 in resting macrophages was also determined and 
graphed as the MFI in CD36+ cells (D). Experiments were performed in triplicate and bars represent the mean ± SD. *p < 0.05, **p < 0.01, ***p < 0.001, compared 
to vehicle-treated cells. The results are representative of at least three independent experiments. None of the treatments altered cell viability as determined by LDH 
release assay (not shown).
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to a lesser extent, also protected LDL from Cu2+-induced oxida-
tion (Figure 2C). Given the importance of the oxidation of the 
protein component in the LDL particle for the physiopathology 
of atherosclerosis, we also tested the potential of biflavonoids to 
prevent oxidation-induced increase of ApoB-100 electronegativ-
ity by REM assay. As shown in Figure 2D, all biflavonoids and 
the BF inhibited the accelerated migration of ApoB-100 in a 
dose-dependent manner. Treatment of LDL with low biflavonoid 
concentrations (1.5 µM) demonstrated a less pronounced effect 
for Vo (Figure 2E). Together, these results show that biflavonoids 
prevent LDL modification at lipid and protein levels and, conse-
quently, reduce the formation of this key atherogenic ligand.
Biflavonoids inhibit the expression of the 
Proatherogenic receptor cD36 in 
Macrophages and Their subsequent 
Transformation into Foam cells
Growing evidence suggest that the direct antioxidant effects 
of flavonoids are insufficient to explain their atheroprotective 
function in vivo and that other mechanisms down stream might 
be more important when their dietary use is considered (13). 
A key step in the “atherogenic pathway” is the uncontrolled surface 
upregulation of the CD36 SR in response to the proatherogenic 
ligand oxLDL, leading to its massive uptake and the subsequent 
progressive transformation of macrophages into foam cells 
(28). Thus, we tested whether biflavonoids interfere with this 
process. Conditions (time and concentration of biflavonoids and 
oxLDL) used for macrophage treatments were previously set to 
assure the preservation of cell viability in the assays (Figure S1 
in Supplementary Material). Flow cytometry histograms showed 
that in the basal state most of macrophages express CD36 at 
high density on the surface, which is further increased after 
exposure to oxLDL [Figure S2A in Supplementary Material (23)]. 
Therefore, it was not surprising that treatments with biflavonoids 
did not alter the percentage of the CD36+ cells (Figure  3A; 
Figure S2A in Supplementary Material). Interestingly, the surface 
density of the CD36 receptor (as determined by the MFI) or the 
frequency of CD36high macrophages was significantly reduced by 
biflavonoid treatment (Figures 3B,C). In the absence of oxLDL 
triggering, no changes were induced on the surface density of 
CD36 by biflavonoid treatment (Figure  3D), indicating that 
biflavonoids are active only when macrophages are acquiring a 
proatherogenic phenotype. The consequences of this biflavonoid-
mediated reduction of CD36 expression on macrophages were 
tested by examining their transformation into foam cells using 
FigUre 4 | Biflavonoids modulate oxidized LDL (oxLDL) uptake and cholesterol accumulation in primary macrophages. Macrophages were preincubated 12 h with 
biflavonoids (45 µM for Mo, Vo, and Fu, and 25 µg/mL for BF) and subsequently incubated with DiI-oxLDL (50 µg/mL) for additional 6 h. Labeled oxLDL–
macrophage uptake was then determined by flow cytometry and graphed as the percentage of DiI-oxLDL+ cells (a), the MFI in DiI-oxLDL+ cells (B), or the 
percentage of DiI-oxLDLhigh cells (c) based on a gating strategy shown in the Figure S2B in Supplementary Material. Under the experimental conditions used in 
these assays, macrophage viability was preserved as shown by LDH release into cell supernatants (D). Parallel biflavonoid-pretreated macrophage cultures (12 h) 
were further incubated in the presence of oxLDL (30 µg/mL) during 36 h and the cellular cholesterol content was determined by GC/MS; a representative 
chromatogram is shown (e). Cholesterol content was calculated based on the peak area of the ion 145 [for details of the method, see Ref. (23)] and expressed as 
microgram cholesterol/106 macrophages (F). Experiments were performed in triplicate and bars represent the mean ± SD. **p < 0.01, ***p < 0.001, compared to 
vehicle-treated cells. The results are representative of at least three independent experiments. Mθ: macrophage.
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the oxLDL uptake assay and by quantifying the accumulation of 
intracellular cholesterol. Results of fluorescently labeled oxLDL 
uptake, both in percentages as well as in MFI (which reveals the 
magnitude of oxLDL loading) closely mirrored those of CD36 
expression (Figures 3A–C and 4A–C; Figure S2 in Supplementary 
Material). Moreover, macrophages treated with Mo or Fu accu-
mulated less cholesterol intracellularly than vehicle-treated cells 
(Figures 4E,F). Taken together, results indicate that biflavonoids 
FigUre 5 | Reactive oxygen species (ROS) and proinflammatory 
cytokine responses of macrophages to oxidized LDL (oxLDL), 
lipopolysaccharide (LPS), and crystal stimulation are modulated by 
biflavonoids. Biflavonoid-pretreated macrophages [12 h; 90 µM for 
Mo, Vo, and Fu, and 50 µg/mL for BF] were further incubated with 
oxLDL (1 h, 50 µg/mL) and ROS production was subsequently 
monitored with the DFC probe by flow cytometry; results are shown as 
the percentage and MFI of DFC+ cells (a). Biflavonoid-pretreated 
macrophages (12 h; 45 µM for Mo, Vo, and Fu, and 25 µg/mL for BF) 
were also stimulated for additional 12 h with oxLDL (25 µg/mL) in 
order to quantify IL-6 secretion (B), or with LPS (10 µg/mL) to quantify 
the secretion of IL-1β, IL-12p70, and MCP-1 (c) into culture 
supernatants. IL-1β release to culture supernatants was also assessed 
in biflavonoid-pretreated cells (12 h; 45 µM for Mo, Vo, and Fu, and 
25 µg/mL for BF) that were subsequently LPS-primed (10 ng/mL) and 
cholesterol crystal (500 μg/mL)-stimulated (D). Cytokine 
quantifications were performed by Luminex. Results are graphed as 
the mean ± SD from triplicate cell cultures. *p < 0.05, **p < 0.01, 
***p < 0.001, compared to vehicle-treated cells. The results are 
representative of at least three independent experiments. None of the 
treatments altered cell viability as determined by LDH release assay 
(not shown).
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from G. madruno are not only able to reduce the formation of the 
proatherogenic ligand oxLDL but also to downregulate its cognate 
endocytic receptor on macrophages, resulting in the attenuation 
of modified lipoprotein uptake and foam cell formation.
rOs Production and Proinflammatory 
cytokine secretion in Proatherogenic 
Macrophages are also inhibited by 
Biflavonoids
Besides foam cell formation, triggering of oxLDL receptors on 
macrophages leads to profound and complex cellular immuno-
metabolic changes that appear to be essential for atherogenesis. 
In vitro and in vivo evidence indicate that the ROS production 
and the secretion of proinflammatory cytokines are crucial com-
ponents of such a response (4). When the highly sensitive probe 
DCFH-DA was used to quantify ROS production in oxLDL-
stimulated macrophages by flow cytometry, a significant reduc-
tion in the frequency of DCF+ cells and the MFI was observed in 
cells pretreated with the biflavonoid Fu (Figure 5A). Mo and Vo 
also inhibited macrophage pro-oxidative response at some extent, 
but differences with vehicle-treated cells did not reach statistic 
significance. We next examined the ability of biflavonoids to 
modulate cytokine secretion in macrophage cultures. First, we 
tested the effects of biflavonoids in resting macrophages and no 
significant proinflammatory activity was evidenced (Figure S3 
in Supplementary Material). Then, we evaluated the effects of 
biflavonoids on the oxLDL-stimulated IL-6 production, since, 
under our experimental conditions, this cytokine is the only one 
induced by oxLDL in macrophages (23). Vo but no other bifla-
vonoids mediated a significant inhibition (Figure 5B). Because 
TLR4 triggers a pathophysiologically relevant pathway in athero-
sclerosis (29), we also determined whether biflavonoids alter the 
cytokine response to the ligand LPS. We found that all cytokines 
tested were robustly upregulated in response to LPS and that all 
aglycone biflavonoids inhibit one or more of the cytokines IL-1β, 
IL-12p70, and MCP-1 with a particular signature (Figure 5C). 
Interestingly, the morelloflavone glycoside Fu was devoid of 
this anti-inflammatory effect. No changes were observed in the 
levels of IL-6, TNFα, or MIP-1α. Finally, given the recognized 
proinflammatory role of cholesterol crystals during atheroscle-
rosis via nucleotide-binding domain and leucine-rich repeat 
containing protein 3 (NLRP3) sensing and assembly (30) we 
analyzed the effect of biflavonoids on cholesterol crystal-induced 
IL-1β secretion using low-dose LPS-primed macrophages, as 
reported previously (23). All biflavonoids were inhibitory in this 
system (Figure  5D), suggesting a potential modulatory effect 
of this group of molecules on NLRP3 inflammasome activity. 
Collectively, our findings confirm that biflavonoids extend their 
antiatherogenic activities by acting on effector proinflammatory 
mediators, such as ROS and cytokines, produced by macrophages 
in response to an array of proatherogenic signals.
a Defined Biflavonoid Fraction (BF) is 
atheroprotective In Vitro and In Vivo
Having demonstrated that biflavonoids inhibit several relevant 
atherogenic events at the oxLDL–macrophage interphase in vitro, 
FigUre 6 | A Garcinia madruno’s BF is atheroprotective in vivo. ApoE−/− mice were treated i.p. with the BF (70 mg/kg, every other day) and fed a western diet, as 
shown (a). Vehicle (DMSO 0.1% in PBS)-treated mice were used as negative controls. After 14 weeks of treatment, sections of the aortic sinus were stained with 
H/E. Representative microphotographs for each treatment group are shown [(B), left]. The size of atherosclerotic lesions was calculated using an image analysis 
software (see Materials and Methods for details). Each point represents the average lesion area (out of 9–12 sections) per mouse [(B), right]. Serum samples from 
same animals were used to quantify total cholesterol levels (c) and MDA concentration (D). Data from individual mice are presented and bars correspond to the 
mean ± SEM. **p < 0.01, ***p < 0.001, compared to control group (Mann–Whitney U test). These results are representative of two independent experiments.
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our next question was whether biflavonoids are atheroprotec-
tive in  vivo. Given the large amounts of biflavonoids required, 
a BF from G. madruno with a defined chemical composition 
(as described in the Section “Materials and Methods”) was pre-
pared for these experiments. First, we confirmed that this biflavo-
noid mix preserved the in vitro properties of its major components 
Mo and Vo. As shown in Figures 2–5, the BF inhibited LDL oxi-
dation (Figures 2C–E), CD36 surface expression (Figures 3B,C), 
oxLDL uptake (Figures  4B,C), and cholesterol accumulation 
(Figures 4E,F), with a potency that reflects its biflavonoids com-
position. Similarly, just like Mo and Vo, the BF was inactive in the 
macrophage ROS production inhibition assay (Figure 5A), and 
in the cytokine response assays to cholesterol crystals, oxLDL, or 
LPS, the presence of BF in cell cultures also reflected its biflavo-
noid composition (Figures 5B–D). Next, we used ApoE−/− mice 
to evaluate the atheroprotective effect of BF administered using 
a route of administration (i.p.) and a scheme (every other day 
during the whole experiment; Figure  6A) that is expected to 
improve the systemic exposure to the active flavonoid aglycones 
(31). Figure  6B shows that, compared to vehicle-treated mice, 
BF-treated mice had significantly smaller atheromatous lesions 
in the aortic sinus (46% reduction). The atheroprotective effect 
FigUre 7 | In vivo atheroprotective effect of the Garcinia madruno’s BF is related to reduced macrophage and T cell infiltration in the atherosclerotic lesions. 
ApoE−/− mice were treated i.p. with the BF and fed a high-fat diet, as shown in Figure 6a. A group of mice treated with vehicle (DMSO 0.1% in PBS) were used as 
controls. After 14 weeks, sections of the aortic sinus were immunostained with macrophage-(MOMA-2) (a) or T cell-(CD3) (B) specific antibodies. Representative 
microphotographs for each treatment group are shown (left). The leukocyte infiltrate in the atherosclerotic lesions was calculated using an image analysis software 
(see Materials and Methods for details). Each point represents the average positive area (out of 9–12 sections) per mouse (right). Data from individual mice are 
presented and bars correspond to the mean ± SEM. **p < 0.01, ***p < 0.001, compared to control group (Mann–Whitney U test). These results are representative 
of two independent experiments.
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of BF at the given dose and scheme was observed in the absence 
of any sign of toxicity, as determined by monitoring of whole 
body weight (Figure S4A in Supplementary Material) or other 
parameters, such as food intake, physical appearance, hydration, 
or behavior, during the experiment (not shown). Biochemical 
hepatotoxicity or pancreatic toxicities were also ruled out, since 
blood levels of hepatic enzymes (AST and ALT) or amylases were 
no modified by BF treatment (Figures S4B–D in Supplementary 
Material). Gross macroscopic appearance of internal organs, 
such as liver, kidneys, spleen, and heart, were similar in treated 
and control mice. Interestingly, serum cholesterol levels, as well 
as the levels of the oxidative stress marker MDA, were lower in 
BF-treated mice (Figures 6C,D), indicating metabolic-modifying 
and oxidation-protective effects of biflavonoids in vivo. En face 
aortic OR+ areas in BF-treated mice showed a trend to lower 
lipid deposition as compared to vehicle-treated mice; however, 
differences were not significant (Figure S5 in Supplementary 
Material). Finally, the effect of BF treatment on the local mac-
rophage and T  cell inflammatory infiltrate was determined by 
immunohistochemical assessment of MOMA-2 and CD3 expres-
sion, respectively, in aortic sinus sections. Macrophage and T cell 
infiltrates were significantly lower in BF-treated mice (63 and 
55% reduction, respectively; Figures 7A,B), which is consistent 
with the reduction of atheroantigen formation/accumulation, 
reduced foam cell formation, and reduced inflammatory response 
observed in  vitro (Figures  2D,E, 4 and 5), demonstrating that 
natural biflavonoids are immunomodulatory in vivo. Collectively, 
these results are in agreement with the in vitro effects described 
in previous sections, and further confirm that biflavonoids have 
hypolipemiant, antioxidant, immunomodulatory, and athero-
protective activity in vivo.
DiscUssiOn
A large body of experimental evidence supports the notion that 
the interaction between macrophages and oxidatively modified 
LDL dictates pathological events in the arterial wall that result 
in the continuous and progressive development of atheromatous 
lesions (4); therefore, atherogenic macrophages are considered 
key therapeutic targets. Flavonoids have been shown to alter 
several aspects of macrophage physiology (23, 32) in a manner 
that suggest that, at least part of their atheroprotective properties, 
are mediated via this cell type. Here, we show that biflavonoids, 
a more restricted class of naturally occurring phytochemicals, 
inhibit the proatherogenic response of macrophages to oxLDL 
in vitro and attenuate atherosclerotic lesion development in vivo. 
Our results expand the understanding of the pharmacology of 
these compounds and stimulate further exploration of their use 
for atherosclerosis and other macrophage-related disorders.
Many studies in  vitro and in  vivo animal models as well as 
human epidemiological and clinical studies support the theory 
that, under hypercholesterolemic conditions, LDL transforma-
tion into oxLDL in the vascular subintimal space triggers primary 
fatty strake formation and subsequent atherosclerotic plaque 
development (33, 34). Retained LDL particles are exposed to ROS 
generated in the arterial wall via several oxidative mechanisms 
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(35), leading to complex chemical processes that result in the for-
mation of oxidatively modified LDL particles, or oxLDL. oxLDLs 
are highly heterogeneous and contain an array of lipid peroxida-
tion products in the lipidic component that are responsible of 
many down stream damaging effects on vascular cells, such as 
cell death, proliferation, migration, and inflammatory response 
(33, 34). In situ oxidation also generates modified derivatives and 
fragments of the apolipoprotein component ApoB-100, which 
function as modified self-ligands triggering foam cell transforma-
tion and further proinflammatory response via innate receptor 
recognition (34, 36). Moreover, modified protein components in 
oxLDL behave as neoantigens for the adaptive immune response 
via T-cell receptor and B-cell receptor stimulation on T and B 
lymphocytes (36), whose proinflammatory effector responses 
are critical in the chronic phase of the disease. It is, therefore, 
reasonable that dietary or pharmacological prevention of LDL 
oxidation represents an interesting intervention strategy, since 
reduced availability of the atherogenic ligand oxLDL would be 
translated into less lipid accumulation, decreased innate and 
adaptive inflammatory responses, and reduced overall damaging 
effects. We found that biflavonoids were as potent as monoflavo-
noids to scavenge ROS (Figures  2A,B), and most importantly, 
protected LDL from Cu2+-induced lipid oxidation (Figure 2C), 
demonstrating that in flavonoid dimers this antioxidant activity 
is preserved. Biflavonoids not only reduced the production of 
lipid peroxides but also prevented structural changes (such as 
increased electronegativity) in the LDL’s apolipoprotein com-
ponent (Figures 2D,E). Our results are consistent with previous 
work reporting free radical scavenging effects of biflavonoids 
and biflavonoid-containing preparations in several systems 
(15, 17, 21, 22), and extend them by showing, for the first time, 
the protective effects of Mo, Vo, and Fu against ApoB-100 modi-
fication. Interestingly, the biflavonoid Mo and its glucoside Fu 
were comparable in their ability to protect LDL, whereas Vo was 
a weaker protector of lipoprotein modification. Considering the 
variety of chemical species formed in the oxLDL particle, these 
observations might be explained by qualitative/quantitatively 
different effects of particular biflavonoids on different reactive 
species. This is of physiological relevance, since relative amounts 
of different chemical species are thought to explain the docu-
mented heterogeneity, and even duality, of oxLDL cellular effects 
[e.g., induction of proliferation/migration versus cell growth 
arrest/apoptosis (37)]. Thus, differential effects of biflavonoids 
on oxLDL composition might impact differently the extent and 
spectrum of potential atherogenic effects of oxLDL on vascular 
cells, such as EC, SMC, or macrophages. Studies addressing the 
effects of biflavonoid-treated oxLDL on those cell types will allow 
to confirm this hypothesis.
Although a key consequence of the increasing atherogenic 
ligand availability in the intimal space is the progressive alteration 
of vascular SMC and EC functions, perhaps the most prominent 
proatherogenic effect of oxLDL is the promotion of macrophage 
to foam cell transformation. This phenomenon critically depends 
on the expression of oxLDL receptors on macrophages, and their 
intracellular signal transduction. Canonical foam cell formation 
results from the uncontrolled oxLDL uptake by resident and 
monocyte-derived immigrant macrophages via SR, such as 
CD36 (28). “Trapping” of foamy macrophages in the intima is 
also CD36-mediated (28), further emphasizing the importance 
of this receptor in the atherosclerotic process. All biflavonoids 
tested here were effective at reducing oxLDL-triggered CD36 
overexpression on macrophages and the subsequent intracellular 
accumulation of cholesterol and transformation into foam cells 
(Figures 3 and 4). Our results are the first to document such effect 
for biflavonoids and are consistent with reports showing similar 
anti-foam cell formation effects exerted by several phytochemi-
cals, including aglycone monoflavonoids, such as Quercetin and 
Kaempferol (23, 38–41), glycoside monoflavonoids (42), and 
glucuronide metabolites (43). The molecular mechanisms under-
lying the CD36 downregulatory effect reported here are yet to be 
investigated. Preliminar evidence with monoflavonoids and other 
phytochemicals points to PPARγ antagonistic effects (38, 42) and 
inhibition of c-Jun-activating protein-1 (AP-1) nuclear translo-
cation (40), but further characterization is required. Results of 
LDL uptake paralleled those of CD36 expression, suggesting that, 
in our system, most of oxLDL internalization occurred via this 
receptor. However, since macrophages also internalize oxLDL 
via SR-A, we cannot rule out a possible role for this SR (44). 
Whereas SR-A does not appear to be downregulated by mono-
flavonoid treatment (40), future studies should evaluate whether, 
besides CD36, biflavonoids also inhibits SR-A expression in 
macrophages. Net cholesterol accumulation in macrophages is 
influenced by two opposite processes, namely influx from oxLDL 
via SR and efflux via ATP-binding cassette (ABC) transport-
ers (28, 44). Whether biflavonoids increase ABC transporters 
expression and, consequently, cholesterol efflux contributing 
to reduced foam cell transformation was not investigated here, 
but it appears as an interesting possibility that requires further 
testing. This mechanism has gained recent attention since many 
monoflavonoids improved reverse cholesterol transport through 
the upregulation of ABC transporters and subsequent increase 
of cholesterol efflux (45–47). Thus, as monoflavonoids appear 
to inhibit foam cell formation through reduced oxLDL uptake 
and increased cholesterol efflux, we speculate that biflavonoids, 
either directly or after their breakdown into monoflavonoids, 
exert similar activities. In support of this hypothesis, a recent 
report documented that Apigenin, one of Vo monoflavonoids, 
promoted cholesterol efflux in macrophages (48). Altogether, our 
results so far indicate that biflavonoids reduce both athero-ligand 
formation and athero-receptor expression, which configurate a 
powerful mechanism for targeting the anatomic and functional 
hallmark of atherosclerosis: the foam cell.
Macrophage recognition of oxLDL and other atherogenic 
ligands triggers, through CD36 and other innate receptors, a 
powerful inflammatory response that fuels and amplifies the 
atherogenic process. The production of ROS and the secretion of 
proinflammatory cytokines make an integral part of this response 
(49). We report here for the first time that Mo, Vo, and Fu inhibit 
oxLDL- or LPS-induced ROS production or proinflammatory 
cytokine secretion in macrophages, with a particular pattern 
(Figures  5A–C). For instance, the glucoside Fu was a weak/
inactive inhibitor of cytokine secretion but effective inhibitor of 
ROS production, whereas the aglycones Mo and Vo exhibited 
the opposite trend. Among aglycones, Mo was the most active 
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inhibiting the Th1-inducing cytokine IL-12, whereas Vo was 
the strongest attenuator of IL-6, MCP-1, and IL-1β production. 
The proatherogenic roles of macrophage-derived ROS and those 
cytokines are well documented and includes the promotion of 
chemotaxis, local/systemic inflammation, T  cell activation, 
apoptosis, and necrosis (49, 50), pointing up to the potential 
antiatherogenic mechanisms of G. madruno’s biflavonoids. A 
number of biflavonoid preparations have been shown to inhibit 
or downregulate enzymes involved in the production of bioactive 
lipids in macrophages, such as phospholipases, cyclooxygenases, 
and lipoxygenases (16). Moreover, some biflavonoids inhibited 
the expression of inducible nitric oxide synthase (iNOS) (and 
subsequent nitric oxide production), cyclooxygenase 2 (COX-2) 
(and subsequent production of lipid mediators, such as prosta-
glandin E2, PGE2), TNFα and other proinflammatory cytokines 
in macrophages (16, 51–54). Those studies, however, were mostly 
performed in macrophage cell lines and generally used LPS as 
a sole stimulus. Our study extends the knowledge to primary 
macrophages with the non-previously tested biflavonoids Mo, 
Vo, and Fu, exploring ROS and cytokine production in the 
context of oxLDL- in addition to LPS-stimulation. The signaling 
pathways involved in the inhibitory effect reported here are yet 
to be investigated. However, taking in consideration the reports 
implicating ERK/c-Fos-AP-1 and ERK/nuclear factor-κB as key 
pathways mediating the iNOS/COX-2-inhibitory effects of the 
biflavonoids Am, Ochnaflavone, and a Ginkgo Biloba extract (53, 
55, 56), we propose that these pathways could play an important 
role. Again, the plethora of signaling pathways and transcription 
factors affected by monoflavonoids (57, 58) represent a collec-
tion of potential targets for biflavonoids and their metabolites 
that will be revealed in the coming years. An interesting recent 
report showed that the biflavonoid mix kolaviron reduced ROS 
and proinflammatory cytokines in LPS-stimulated microglial 
cells and this effect was dependent on the nuclear factor eryth-
roid 2-related factor 2/antioxidant responsive element [Nrf-2/
antioxidant responsive element (ARE)] pathway (59). Nrf-2/
ARE has been emerging as a key indirect antioxidant and 
anti-inflammatory pathway triggered by phytochemicals, such 
as flavonoids, with relevance in various inflammatory diseases 
(60, 61), including atherosclerosis (62). Further investigations 
with other biflavonoids are assured.
Interleukin-1β is a proinflammatory cytokine with increasing 
pathophysiological and therapeutic relevance in atherosclerosis 
and, more generally, in sterile inflammation (30, 63). Basic 
research indicates that oxLDL mediates a CD36-dependent 
endocytic pathway leading to ligand accumulation, cholesterol 
nucleation, and crystal formation (64), as well as pro-IL-1β pro-
duction (65). Later, cholesterol crystals promote lysosomal dis-
ruption, NLRP3 inflammasome activation and subsequent IL-1β 
maturation via caspase-1-dependent proteolysis (66). Being a key 
“upstream” inflammatory mediator in CVD (67), the targeting 
of IL-1β actions with anti-cytokine or anti-receptor mAb has 
emerged as a promising therapeutic option (67, 68). Moreover, 
preventing IL-1β production with NLRP3 small molecule inhibi-
tors has also gained recent attention (69). When we assessed the 
effect of biflavonoids on cholesterol crystal-induced IL-1β secre-
tion by macrophages, we found a significant inhibitory effect 
(Figure  5D), suggesting that biflavonoids might act as NLRP3 
inflammasome inhibitors. Future experimental settings that 
allow separating a possible NLRP3-inhibitory effect (signal 2) 
from the pre-IL-1β downregulatory activity (signal 1) will 
permit the confirmation of this hypothesis. In support of this, a 
similar suggestive observation was made with the monoflavonoid 
quercetin (23), which was recently confirmed as a direct inhibi-
tor of the NLRP3 inflammasome activation via interference with 
the oligomerization of the adaptor protein apoptosis-associated 
speck-like protein containing a CARD (70). Phytochemicals, 
such as flavonoids, are typically effective in diseases where IL-1β 
production and NLRP3 inflammasome activation make part of 
the pathophysiology, and growing evidence support the action of 
these compounds on NLRP3 activation (71). Thus, biflavonoids/
monoflavonoids could represent a novel class of small molecule 
NLRP3 inflammasome inhibitors.
Consistent with the in vitro atheroprotective effects of bifla-
vonoids in macrophages, i.p. administration of the BF attenuated 
atherosclerosis development in vivo, and this effect was accom-
panied by less oxidative stress, a reduction in macrophages and 
T cells infiltrating atherogenic plaques and by lower plasma cho-
lesterol levels (Figures 6 and 7). Although a causal relationship 
remains to be established, we propose that the antiatherogenic 
effects of BF evidenced in primary macrophages in  vitro also 
operate in vivo and explain, at least in part, the effects of BF in 
dyslipidemic mice. Pinkaew and cols reported that diet sup-
plementation with Mo, the majority biflavonoid in our BF, also 
induced significant atheroprotection (18) that was associated 
with reduced migration of SMC to the intimal space but not with 
reduced oxidative stress, hypocholesterolemic effects, or changes 
in macrophage density in the aortic sinus. Discrepancies between 
the two studies could be explained by different experimental set-
tings, such as different genetic background of the animals, oral 
versus i.p. administration, chow versus HFD diets, different dura-
tion of treatments, or different composition of the biflavonoid 
preparation. It is possible that biflavonoids exert atheroprotection 
via both SMC and macrophage-intrinsic effects. Moreover, the 
observation that Mo inhibits angiogenesis in vitro and in vivo (19) 
makes tempting to propose that atheroprotective actions of this 
biflavonoid also involve the third key cell in the vascular wall, 
the EC. Mechanistic studies have indicated that Mo alters SMC 
and EC migration by targeting migration-related kinases, such as 
focal adhesión kinase, s-Src and ERK, and small GTPases, such as 
RhoA and Rac1 (19, 20). It will be interesting to confirm whether 
Mo also alters macrophage migration and whether similar 
signaling pathways are inhibited in proatherogenic macrophages.
Although very little is known on the bioavailability and 
biotransformation of biflavonoids (16, 17), they surely follow 
the same rules of monoflavonoids, this is, short half-life, rapid 
conjugation and excretion, and intestinal transformation by 
microorganisms. The reduced anti-inflammatory activity in vivo 
upon oral administration compared to i.p. administration is 
likely the result of the poor oral bioavailability of biflavonoids 
and/or active biflavonoid metabolites (16). One study reported 
that after oral Mo supplementation (200  mg/kg/day) in mice, 
blood levels of Mo were almost indetectable [1.37  µM; (20)]. 
Although measurements of the serum levels or tissue distribution 
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of biflavonoids were not performed in our work, we chose 
chronic i.p. administration (70 mg/kg/every other day) in order 
to assure systemic exposure to biflavonoid or their potentially 
active metabolites during the whole experiment. This strategy 
allowed evidencing the antioxidant, hypocholesterolemic and 
anti-inflammatory effects of the BF (Figures 6 and 7). In Pinkaew’s 
atheroprotection study, a very low dose of oral Mo (4 mg/kg/day) 
that is expected to yield very low (submicromolar range) serum 
concentrations (18) was used. However, reduced SMC migration 
and significant atheroprotection (as assessed by atheromatous 
plaque size) was observed, in the absence of hypocholesterolemic, 
antioxidant, or anti-inflammatory effects. As suggested by the 
study where Mo inhibited directly the HMG-CoA Reductase 
(72), a hypocholesterolemic effect of Mo would require systemic 
concentrations hardly reached by oral low-dose administration 
but possibly reached after parenteral injections (73). Likewise, 
in vivo antioxidant and anti-inflammatory effects might require 
higher circulating levels of Mo than those reported/expected in 
Pinkaew’s studies (18, 20). On the bases of the recent hypothesis 
of a “xenobiotic-like” effect of flavonoids (13), it is possible that 
lower MDA levels and reduced inflammatory infiltrate observed 
in our work were the result of “indirect” antioxidant and anti-
inflammatory effects promoted by biflavonoid actions on the 
Nrf-2/ARE axis (59–62). The extent of these effects and, therefore, 
the range of atherogenic processes and cells that are targeted 
by biflavonoids in  vivo could be influenced by factors such as 
dose/scheme/via of administration or purity/complexity of the 
biflavonoid preparation (18–20). Adding more complexity to 
the biflavonoid’s pharmacology, it is currently unknown whether 
biological effects of biflavonoids are due to their breakdown into 
monoflavonoids or to intrinsic structural features. In favor of 
the first hypothesis is the observation that biological/pharma-
cological characteristics of biflavonoids and monoflavonoids are 
largely overlapping. For instance, monoflavonoids conforming 
the biflavonoids reported here, such as naringenin, apigenin, 
or luteolin are also endowed with anti-foam cell, antioxidant/
anti-inflammatory and/or atheroprotective properties (16, 45, 
47, 57, 58). However, evidence also argues toward the alterna-
tive hypothesis, since some activities of BF are not reproduced 
with their monoflavonoid counterparts (74, 75). Furthermore, as 
shown with dimeric (and polymeric) procyanidins (76), an array 
of active metabolites can be generated by microbial decomposi-
tion of mono and biflavonoids to phenolic acids. Thus, activities 
of biflavonoids might well result from a complex combination of: 
(i) direct effects of the biflavonoid and conjugated biflavonoids, 
(ii) effects of the conjugated/unconjugated biflavonoid-derived 
monoflavonoids, and (iii) effects of the conjugated/unconjugated 
microbial-derived decomposition products. This scenario widens 
the spectrum of potential targets and makes the understanding of 
biflavonoid activities even more challenging.
In summary, we have shown information demonstrating 
the atheroprotective activity in  vivo and in  vitro macrophage- 
intrinsic effects for biflavonoids. Improving our understanding of 
the mechanisms of action of these phytochemicals will increase 
their preventive and therapeutic potential for cardiovascular 
and other inflammatory diseases where macrophages and 
macrophage-related cells play pathogenic and/or protective roles.
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FigUre s1 | Viability of macrophage cultures in response to oxLDL or 
biflavonoids. Macrophages were treated during the indicated time and with the 
indicated amounts of oxLDL (a) or biflavonoid preparations (B) to determine cell 
viability by measuring LDH activity in the supernatants. Vehicle and a cell lysis 
solution were used as controls. Experiments were performed in triplicate, and 
bars represent the mean ± SD.
FigUre s2 | Flow cytometry analysis of CD36 surface expression and oxLDL 
uptake by macrophages after treatments. The effect of biflavonoids (here only Mo 
is shown as a representative example) on CD36 expression (a) or oxLDL uptake 
(B) in macrophages was investigated by flow cytometry (as explained in Materials 
and Methods). Representative histograms for the indicated condition are shown. 
Controls for CD36 expression under resting [(a), left] or oxLDL-stimulation 
conditions [(a), middle] are shown for comparison. Controls for non-fluorescent 
[(B), left] or fluorescent oxLDL (DiI-oxLDL) uptake [(B), middle] are also shown for 
comparison. Bars on the histograms indicate CD36+ and CD36high macrophages 
as well as DiI-oxLDL+ and DiI-oxLDLhigh macrophages. I: isotype controls. Mθ, 
macrophages.
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FigUre s3 | Effect of biflavonoids on proinflammatory cytokine production in 
resting macrophages. Macrophages were treated with biflavonoids (24 h; 45 µM 
for Mo, Vo, and Fu, and 25 µg/mL for BF) or vehicle and the secretion of 
proinflammatory cytokines IL-6 (a), IL-1β (B), TNFα (c), MCP-1 (D), MIP-1α  
(e), and IL-12p70 (F) was evaluated by Luminex. LPS (10 μg/mL)-treated 
macrophages were used as positive control. Experiment was performed in 
triplicate and bars represent the mean ± SD.
FigUre s4 | Treatment with Garcinia madruno’s BF does not alter mouse 
body weight or clinical biochemistry parameters. ApoE−/− mice were treated i.p. 
with the biflavonoid fraction (70 µg/kg), as shown in Figure 6a. Total body 
weight was monitored weekly and compared to vehicle-treated mice 
(a). Serum samples were obtained from animals at the end of treatments and 
the levels of aspartate transaminase (AST) (B), alanine transaminase (ALT) (c), 
and amylase (D) were determined. Body weight results are shown as the 
mean ± SEM, whereas biochemical parameters of mice are shown individually 
with bars indicating the mean ± SEM. No significant differences were found 
between the two groups. Dotted lines represent normal reference ranges for 
each analyte.
FigUre s5 | Evaluation of the effect of BF treatment on aortic lipidic deposition 
in ApoE−/− mice. ApoE−/− mice were treated i.p. with the biflavonoid fraction 
(70 µg/kg), as shown in Figure 6a. Vehicle-treated mice were used as negative 
controls. After sacrifice, aortas (from ascendant to abdominal) were removed, 
opened longitudinally, and stained with Oil Red O. Oil Red+ positive areas were 
calculated with the aid of image analysis software. Results are shown individually 
with bars indicating the mean ± SEM. No significant differences were found 
between the two groups.
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